The selective ablation of inflammation in an acute stage of ischemic stroke may be a new strategy to promote neurogenesis.
Ischemic stroke is one of the most common diseases in the world. Pre-clinical studies have proved that stem cell therapy is effective in treating ischemic stroke. But there is a "time window" for stem cell therapy that is only limited in acute/subacute stage after stroke. Meanwhile, ischemic stroke can elicit an immediate neuroinflammatory reaction in the brain, and an uncontrolled inflammatory process in acute/subacute stage will impair survival of stem cells and block repair processes. A selective ablation of harmful inflammation factors can greatly decrease a hostile environment and facilitate neurogenesis. If detrimental factors of inflammation in an acute/subacute stage after an ischemic stroke are suitably handled and more specific immunomodulatory interventions are adopted, neurogenesis in the "time window" will greatly enhanced.
Institute of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, PR China.
Jie
J
Zhou
Gang
G
Cheng
Ronghua
R
Kong
Da-Kuan
DK
Gao
Xiang
X
Zhang
D000818:Animals; D002545:Brain Ischemia / Q000473:pathology*; D006801:Humans; D007249:Inflammation / Q000473:pathology / Q000628:therapy*; D055495:Neurogenesis; D051381:Rats; D020521:Stroke / Q000473:pathology*